Abstract
The genetics of Alzheimers disease (AD) implies that restoring non-pathological levels or ratios of different amyloid-β (Aβ) peptide species in the brain could prevent the onset or delay the progression of this neurodegenerative disease. In particular, a selective reduction of the longer Aβ(1-42) peptide which is widely believed to be causative of AD is currently seen as an attractive approach for a disease-modifying therapy. Based on the knowledge that Aβ(1-42) and various shorter Aβ peptides are generated by the same γ-secretase enzyme, the concept of allosteric modulation of the cleavage specificity of this aspartic protease has been introduced to the field of protease drug discovery and fuelled novel medicinal chemistry efforts. γ-Secretase modulation holds the promise that chemical entities can be synthesized which restore non-pathological enzyme activity by shifting the actual substrate cleavage towards the generation of shorter Aβ peptides. It can be assumed that this approach has gained considerable attraction for pharmaceutical drug discovery since the development of non-selective protease inhibitors for γ-secretase has been proven to be difficult due to inherent mechanism-based liabilities.
Current Topics in Medicinal Chemistry
Title: γ-Secretase Modulation and its Promise for Alzheimers Disease: a Rationale for Drug Discovery
Volume: 8 Issue: 1
Author(s): Dirk Beher
Affiliation:
Abstract: The genetics of Alzheimers disease (AD) implies that restoring non-pathological levels or ratios of different amyloid-β (Aβ) peptide species in the brain could prevent the onset or delay the progression of this neurodegenerative disease. In particular, a selective reduction of the longer Aβ(1-42) peptide which is widely believed to be causative of AD is currently seen as an attractive approach for a disease-modifying therapy. Based on the knowledge that Aβ(1-42) and various shorter Aβ peptides are generated by the same γ-secretase enzyme, the concept of allosteric modulation of the cleavage specificity of this aspartic protease has been introduced to the field of protease drug discovery and fuelled novel medicinal chemistry efforts. γ-Secretase modulation holds the promise that chemical entities can be synthesized which restore non-pathological enzyme activity by shifting the actual substrate cleavage towards the generation of shorter Aβ peptides. It can be assumed that this approach has gained considerable attraction for pharmaceutical drug discovery since the development of non-selective protease inhibitors for γ-secretase has been proven to be difficult due to inherent mechanism-based liabilities.
Export Options
About this article
Cite this article as:
Beher Dirk, γ-Secretase Modulation and its Promise for Alzheimers Disease: a Rationale for Drug Discovery, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334051
DOI https://dx.doi.org/10.2174/156802608783334051 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Orexigenic / Anorexigenic Signals in Bulimia Nervosa
Current Molecular Medicine In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters
Current Topics in Medicinal Chemistry Obstructive Sleep Apnea and Atrial Arrhythmogenesis
Current Cardiology Reviews Editorial (Hot Topic: G Protein-Coupled Receptor Biased Agonism: Development Towards Future Selective Therapeutics)
Mini-Reviews in Medicinal Chemistry Topical Nano-emulgel for Skin Disorders: Formulation Approach and Characterization
Recent Patents on Anti-Infective Drug Discovery From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)
Current Topics in Medicinal Chemistry Glycosaminoglycans, Protein Aggregation and Neurodegeneration
Current Protein & Peptide Science Pavlovian Sign-Tracking Model of Alcohol Abuse
Current Drug Abuse Reviews Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Aza-Diels-Alder Reaction: An Efficient Approach for Construction of Heterocycles
Current Organic Chemistry Frailty Among Alzheimer’s Disease Patients
CNS & Neurological Disorders - Drug Targets Chemical Exchange Saturation Transfer (CEST) Imaging of pH
Neuroscience and Biomedical Engineering (Discontinued) Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine Neuroprotective Mechanisms as Treatment Strategy in Alzheimers disease
Current Medicinal Chemistry - Central Nervous System Agents Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry Metabolomics Applications in Precision Medicine: An Oncological Perspective
Current Topics in Medicinal Chemistry